Ondrej Fiala1,2, Petr Hosek2, Milos Pesek3, Jindrich Finek4, Jaroslav Racek5, Pavel Stehlik5, Ondrej Sorejs4, Marek Minarik6,7, Lucie Benesova6, Adam Celer4, Ivana Nemcova4, Radek Kucera8, Ondrej Topolcan8. 1. Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic fiala.o@centrum.cz. 2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 3. Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. 4. Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. 5. Institute of Clinical Biochemistry and Haematology, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic. 6. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. 7. Department of Analytical Chemistry, Faculty of Sciences, Charles University, Prague, Czech Republic. 8. Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Abstract
BACKGROUND: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment. RESULTS: There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353). CONCLUSION: Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinib toxicity. Copyright
BACKGROUND:Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment. RESULTS: There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353). CONCLUSION:Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinibtoxicity. Copyright
Authors: Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain Journal: Biomed Res Int Date: 2022-06-28 Impact factor: 3.246
Authors: Koen G A M Hussaarts; G D Marijn Veerman; Robert Peric; Esther Oomen-de Hoop; Kersten D Landa; Cor H van der Leest; Suzanna D Broerse; Hugo B Rutten; Huub N A Belderbos; Christi M J Steendam; Marthe S Paats; Stijn L W Koolen; Anne-Marie C Dingemans; Teun van Gelder; Roelof W F van Leeuwen; Joachim G J V Aerts; Ron H J Mathijssen Journal: Clin Pharmacokinet Date: 2021-01 Impact factor: 6.447